- Biotechnology company PureTech Health said affiliate Vedanta Biosciences had initiated a clinical study regarding an immuno-oncology candidate in patients with types of advanced or metastatic cancer.

The open-label, non-randomised study would evaluate the safety, tolerability and clinical activity of the treatment, called VE800.

The parameters would be measured in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo.

Vedanta would target enrolment of over 100 patients in the US diagnosed with advanced or metastatic melanoma, gastric/gastroesophageal junction adenocarcinoma or microsatellite-stable colorectal cancer.

Story provided by